MYL12A (myosin light chain 12A) is a regulatory subunit of myosin II that modulates contractile activity through phosphorylation-dependent mechanisms 1. MYL12A functions as an essential structural component that maintains myosin II stability and cellular integrity; knockdown studies demonstrate that normal MYL12A levels are critical for preserving myosin heavy chain (MYH9/MYH10) and essential light chain (MYL6) levels in fibroblasts 1. Beyond its canonical role in muscle contraction, MYL12A participates in non-muscle processes including cytokinesis and cell migration 2. Disease relevance spans multiple pathological contexts. In diffuse large B-cell lymphoma (DLBCL), MYL12A undergoes deubiquitination by the OTUD3 enzyme to promote cell survival, and inhibiting this pathway with Rupatadine shows therapeutic potential 3. MYL12A emerges as a prognostic biomarker in glioblastoma, where it localizes to tumor-immune microenvironment interfaces and correlates with immune infiltration 4. Altered MYL12A expression associates with tetralogy of Fallot congenital heart disease 5, brain lower grade glioma prognosis 6, severe fever with thrombocytopenia syndrome pathogenesis 7, and ankylosing spondylitis immune dysregulation 8. These findings suggest MYL12A serves dual roles: maintaining cellular mechanical properties while also functioning in disease-associated immune and inflammatory processes.